Sandu Pharma.

Who are the top shareholders of the Sandu Pharma.?

The top shareholders of Sandu Pharma are Umesh Bhaskar Sandu with 14.37%, and Sanmark Realty And Finance Private Limited with 5.63%. Individual investors collectively own 35.9% of the shares, with no institutional or mutual fund holdings.

The top shareholders of Sandu Pharma include Umesh Bhaskar Sandu, who holds the highest promoter stake at 14.37%. Additionally, Sanmark Realty And Finance Private Limited is the largest public shareholder with a holding of 5.63%. Individual investors collectively hold 35.9% of the shares. There are no institutional investors or mutual funds currently holding shares in the company.

Who are in the management team of Sandu Pharma.?

As of March 2022, the management team of Sandu Pharma includes Umesh B Sandu (Managing Director), Pratika Mhambray (Company Secretary), and several Non-Executive Directors: Dilip R Salgaocar, Krishna B Deshpande, Madan Laxman Kapre, K Vinay Kumar, Shashank B Sandu, and Shubhada P Sandu. Each member plays a key role in the company's governance and operations.

As of March 2022, the management team of Sandu Pharma includes the following members:<BR><BR>1. Umesh B Sandu - Managing Director<BR>2. Pratika Mhambray - Company Secretary & Compliance Officer<BR>3. Dilip R Salgaocar - Non-Executive & Independent Director<BR>4. Krishna B Deshpande - Non-Executive & Independent Director<BR>5. Madan Laxman Kapre - Non-Executive & Independent Director<BR>6. K Vinay Kumar - Non-Executive & Independent Director<BR>7. Shashank B Sandu - Non-Executive & Non-Independent Director<BR>8. Shubhada P Sandu - Non-Executive & Non-Independent Director<BR><BR>Each member holds a specific role within the organization, contributing to its governance and operations.

What does Sandu Pharma. do?

Sandu Pharmaceuticals Ltd manufactures and trades Ayurvedic medicines, operating as a Micro Cap company since 1985. As of March 2025, it reported net sales of 14 Cr and a market cap of Rs 50 Cr.

Overview:<BR>Sandu Pharmaceuticals Ltd is engaged in the manufacturing and trading of Ayurvedic medicines and operates within the Pharmaceuticals & Biotechnology industry, classified as a Micro Cap company.<BR><BR>History:<BR>Established in 1985, Sandu Pharmaceuticals Ltd has been involved in the Ayurvedic medicine sector since its inception. The company reported its latest quarterly results for March 2025, showing net sales and net profit figures.<BR><BR>Financial Snapshot:<BR>Net Sales: 14 Cr (Quarterly Results - Mar 2025) <BR>Net Profit: 0 Cr (Quarterly Results - Mar 2025) <BR>Market Cap: Rs 50 Cr (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: 32.00 <BR>Industry P/E: 30 <BR>Dividend Yield: 1.55% <BR>Debt-Equity: -0.05 <BR>Return on Equity: 3.71% <BR>Price to Book: 1.19 <BR><BR>Contact Details:<BR>Address: Plot No 25/26/29 & 30, Pilerne Indl Estate Marra Bard Bardez Goa : 403511 <BR>Website: http://www.sandu.in

Has Sandu Pharma. declared dividend?

Sandu Pharmaceuticals Ltd has declared an 8% dividend, amounting to ₹0.80 per share, with an ex-date of September 19, 2024. While recent total returns show declines over shorter periods, the company has experienced substantial gains over the longer term.

Sandu Pharmaceuticals Ltd has declared an 8% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 8%<BR>- Amount per share: ₹0.80<BR>- Ex-date: 19 Sep 2024<BR><BR>Dividend Yield: 1.55%.<BR><BR>Total Returns by Period:<BR>Over the 6-month period, the price return was -12.48%, with a dividend return of 0%, resulting in a total return of -12.48%.<BR><BR>In the 1-year period, the price return was -16.07%, the dividend return was 1.34%, leading to a total return of -14.73%.<BR><BR>For the 2-year period, the price return was -11.88%, the dividend return was 2.55%, culminating in a total return of -9.33%.<BR><BR>During the 3-year period, the price return was -25.96%, with a dividend return of 3.55%, resulting in a total return of -22.41%.<BR><BR>In the 4-year period, the price return was 25.8%, the dividend return was 4.83%, producing a total return of 30.63%.<BR><BR>Over the 5-year period, the price return was 220.0%, with a dividend return of 14.52%, leading to a total return of 234.52%.<BR><BR>Overall, Sandu Pharmaceuticals Ltd has declared a dividend, but the total returns over various periods show a mixed performance, with significant declines in shorter periods and substantial gains over the longer term. The recent dividend declaration may provide some relief to investors amidst the fluctuating returns.

Who are the peers of the Sandu Pharma.?

Sandu Pharma's peers include Sun Pharma, Divi's Lab, Cipla, Torrent Pharma, Dr Reddy's Labs, Transchem, Shelter Pharma, Chandra Bhagat, and Mono Pharmacare. In terms of management risk, growth, and capital structure, Sandu Pharma ranks lower than several peers, with a 1-year return of -9.50%.

Peers: The peers of Sandu Pharma. are Sun Pharma.Inds., Divi's Lab., Cipla, Torrent Pharma, Dr Reddy's Labs, Transchem, Shelter Pharma, Chandra Bhagat, Mono Pharmacare.<BR><BR>Quality Snapshot: Excellent management risk is observed at Sun Pharma.Inds., Cipla, Dr Reddy's Labs, and Shelter Pharma, while Good management risk is found at Divi's Lab., Torrent Pharma, and Sandu Pharma. Below Average management risk is present at Chandra Bhagat, Mono Pharmacare, and the rest. Growth is Excellent for Sun Pharma.Inds., Cipla, and Dr Reddy's Labs, while Below Average growth is noted for Divi's Lab., Torrent Pharma, Sandu Pharma., Chandra Bhagat, and the rest. Excellent capital structure is seen at Sun Pharma.Inds., Cipla, Dr Reddy's Labs, and Shelter Pharma, while Good capital structure is found at Torrent Pharma and Sandu Pharma., and Below Average capital structure is present at Transchem, Chandra Bhagat, Mono Pharmacare, and the rest.<BR><BR>Return Snapshot: Divi's Lab. has the highest 1-year return at 51.69%, while Chandra Bhagat has the lowest at -42.15%. Sandu Pharma.'s 1-year return is -9.50%, which is lower than both of these peers. Additionally, Transchem, Shelter Pharma, Chandra Bhagat, and Mono Pharmacare all have negative six-month returns.

What is the technical trend for Sandu Pharma.?

As of June 5, 2025, Sandu Pharma's technical trend is mildly bearish, with mixed signals from indicators like the weekly MACD being mildly bullish and the monthly MACD remaining bearish, alongside bearish weekly RSI and daily moving averages.

As of 5 June 2025, the technical trend for Sandu Pharma has changed from bearish to mildly bearish. The weekly MACD is mildly bullish, but the monthly MACD remains bearish, indicating mixed signals. The weekly RSI is bearish, while the monthly RSI shows no signal, suggesting weakness in momentum. Moving averages on the daily chart are mildly bearish, reinforcing the negative sentiment. Bollinger Bands indicate a mildly bullish stance on the weekly but bearish on the monthly, adding to the mixed outlook. The KST is mildly bullish weekly but bearish monthly, and Dow Theory shows a mildly bearish trend on the weekly with no trend on the monthly. Overall, the current stance is mildly bearish, with key indicators like the daily moving averages and the monthly MACD contributing to this view.

How big is Sandu Pharma.?

As of 24th July, Sandu Pharmaceuticals Ltd has a market capitalization of 48.00 Cr, with recent net sales of 67.19 Cr and a net profit of 1.56 Cr. The company reported shareholder's funds of 40.59 Cr and total assets of 52.41 Cr for the annual period ending in March 2024.

As of 24th July, Sandu Pharmaceuticals Ltd has a market capitalization of 48.00 Cr, categorizing it as a Micro Cap company.<BR><BR>In the latest four quarters, Sandu Pharmaceuticals reported Net Sales of 67.19 Cr and a Net Profit of 1.56 Cr.<BR><BR>For the latest annual period ending in March 2024, the company had Shareholder's Funds amounting to 40.59 Cr and Total Assets of 52.41 Cr.

Are Sandu Pharma. latest results good or bad?

Sandu Pharmaceuticals' latest results are unfavorable, with a 18.1% decline in net sales and a 41.07% drop in net profit for the quarter ending March 2025, leading to a 'Strong Sell' rating from MarketsMOJO due to serious financial concerns.

The latest results for Sandu Pharmaceuticals indicate a challenging financial performance. For the quarter ending March 2025, the company reported net sales of Rs 14.07 crore, which is a significant decline of 18.1% compared to the average net sales of Rs 17.18 crore over the previous four quarters. This figure represents the lowest net sales for Sandu Pharmaceuticals in the last five quarters.<BR><BR>Additionally, the company's consolidated net profit saw a sharp decrease of 41.07%, reflecting ongoing difficulties in maintaining profitability. The operating profit also experienced a decline of 54.55%. Given these results, MarketsMOJO has issued a 'Strong Sell' rating for the company, indicating serious concerns about its financial health and future prospects.<BR><BR>Overall, the financial results suggest that Sandu Pharmaceuticals is facing significant challenges, making the latest performance appear unfavorable.

When is the next results date for Sandu Pharma.?

The next results date for Sandu Pharma is 12 November 2025.

The next results date for Sandu Pharma is scheduled for 12 November 2025.

How has been the historical performance of Sandu Pharma.?

Sandu Pharma has shown stable financial performance, with net sales slightly decreasing from 67.28 Cr in Mar'24 to 67.19 Cr in Mar'25, while operating profit and profit after tax increased modestly. Total assets rose from 52.41 Cr to 55.72 Cr, indicating consistent asset management.

Answer:<BR>The historical performance of Sandu Pharma shows a relatively stable financial trajectory over the past few years.<BR><BR>Breakdown:<BR>Sandu Pharma's net sales have remained consistent, with a slight decrease from 67.28 Cr in Mar'24 to 67.19 Cr in Mar'25, following a gradual increase from 65.35 Cr in Mar'23 and 65.50 Cr in Mar'22. The total operating income mirrored this trend, reflecting the same figures as net sales. The total expenditure, excluding depreciation, decreased slightly from 64.99 Cr in Mar'24 to 64.43 Cr in Mar'25, contributing to an operating profit (PBDIT) increase from 2.71 Cr to 2.93 Cr during the same period. Profit before tax also saw a modest rise from 2.07 Cr in Mar'24 to 2.16 Cr in Mar'25, while profit after tax increased from 1.46 Cr to 1.55 Cr. The earnings per share (EPS) improved from 1.51 in Mar'24 to 1.6 in Mar'25, although it has decreased from 1.8 in Mar'22. On the balance sheet, total assets rose from 52.41 Cr in Mar'24 to 55.72 Cr in Mar'25, with total liabilities also increasing from 52.41 Cr to 55.72 Cr. The cash flow results indicate a stable cash position, with closing cash and cash equivalents remaining at 1.00 Cr for both Mar'25 and Mar'24. Overall, Sandu Pharma has demonstrated steady performance with slight fluctuations in profitability and consistent asset management.

Is Sandu Pharma. overvalued or undervalued?

As of November 21, 2025, Sandu Pharma is considered undervalued with an attractive valuation grade, featuring a PE ratio of 24.77, an EV to EBITDA of 13.26, and a Price to Book Value of 0.92, significantly lower than its peers, despite a year-to-date stock decline of 30.14% compared to the Sensex's gain of 9.08%.

As of 21 November 2025, the valuation grade for Sandu Pharma has moved from fair to attractive, indicating a positive shift in its valuation outlook. The company is currently assessed as undervalued based on its financial metrics. Key ratios include a PE ratio of 24.77, an EV to EBITDA of 13.26, and a Price to Book Value of 0.92, which suggest that the stock is trading at a reasonable valuation compared to its earnings and asset base.<BR><BR>In comparison to its peers, Sandu Pharma's PE ratio is significantly lower than that of Elitecon International, which stands at 239.98, and MMTC, which has a PE of 133.45. This positions Sandu Pharma favorably within the pharmaceuticals and biotechnology sector, especially when considering its attractive valuation grade. Notably, the company's recent stock performance has lagged behind the Sensex, with a year-to-date decline of 30.14% compared to the Sensex's gain of 9.08%, further reinforcing the notion that it may be undervalued in the current market environment.

Should I buy, sell or hold Sandu Pharmaceuticals Ltd?

Why is Sandu Pharmaceuticals Ltd falling/rising?

As of 26-Mar, Sandu Pharmaceuticals Ltd's stock price is at 34.00, reflecting a 2.41% increase after two days of decline. Despite this short-term rise, the stock has a year-to-date drop of 9.16% and a significant decline of 32.00% over the past year, with decreasing investor participation indicating potential future challenges.

As of 26-Mar, Sandu Pharmaceuticals Ltd's stock price is rising, currently at 34.00, reflecting an increase of 0.8 or 2.41%. This upward movement follows a trend reversal after two consecutive days of decline. The stock has shown a performance today that is in line with the sector, which has gained by 2.48%. Additionally, the stock's current price is higher than its 5-day moving averages, indicating a short-term positive trend, although it remains lower than the 20-day, 50-day, 100-day, and 200-day moving averages.<BR><BR>Despite this rise, it is important to note that the stock has experienced a significant decline over longer periods, with a year-to-date drop of 9.16% and a one-year decline of 32.00%. Furthermore, there has been a notable decrease in investor participation, as evidenced by a delivery volume that has fallen by 91.39% compared to the 5-day average. This suggests that while the stock is currently rising, the overall investor interest may be waning, which could impact future price movements.

Why is Sandu Pharmaceuticals Ltd falling/rising?

As of 27-Mar, Sandu Pharmaceuticals Ltd's stock price is at 33.36, reflecting a decline of 1.88%. The stock has underperformed significantly over various periods, including a year-to-date drop of 10.87% and a 27.84% decrease over the past year, indicating a bearish trend.

As of 27-Mar, Sandu Pharmaceuticals Ltd's stock price is falling, currently at 33.36, which reflects a decrease of 0.64 or 1.88%. This decline is evident in the stock's performance over various periods, showing a 1-week drop of 3.19% and a 1-month decrease of 4.69%. Year-to-date, the stock has fallen by 10.87%, and over the past year, it has decreased by 27.84%. <BR><BR>In comparison to the benchmark Sensex, Sandu Pharmaceuticals has underperformed significantly, with a 3-year decline of 36.09% against a 27.63% increase in the Sensex. Additionally, the stock is trading below its moving averages across all time frames, indicating a bearish trend. <BR><BR>Today's trading activity also reflects negative sentiment, with the stock underperforming the sector by 0.52% and a notable drop in investor participation, as evidenced by a 61.73% decrease in delivery volume compared to the 5-day average. Overall, these factors contribute to the ongoing decline in Sandu Pharmaceuticals Ltd's stock price.

Why is Sandu Pharmaceuticals Ltd falling/rising?

As of 28-Mar, Sandu Pharmaceuticals Ltd's stock price is declining, currently at 33.36, reflecting a -1.88% change. This decline is driven by significant underperformance against benchmarks, weak fundamentals, declining investor interest, and reduced promoter confidence.

As of 28-Mar, Sandu Pharmaceuticals Ltd is experiencing a decline in its stock price, currently at 33.36, which reflects a change of -0.64 or -1.88%. This downward movement can be attributed to several factors highlighted in the provided data. <BR><BR>Firstly, the stock has underperformed significantly compared to the benchmark indices, with a one-year return of -27.84%, while the BSE500 has only declined by 5.18% during the same period. Additionally, the stock has consistently lagged behind the benchmark over the last three years, indicating a trend of underperformance.<BR><BR>Moreover, the stock is trading below its moving averages across various time frames, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, which suggests a bearish trend. Today's performance also indicates that the stock has outperformed its sector by only 0.52%, but this is overshadowed by the overall negative sentiment in the market, where trading in the sector has fallen by -2.42%.<BR><BR>Investor participation appears to be declining, as evidenced by a significant drop in delivery volume, which fell by -61.73% compared to the 5-day average. This reduction in trading activity may reflect waning interest from investors.<BR><BR>Additionally, the company's fundamentals show weak long-term growth potential, with a low return on equity (ROE) of 3.73% and modest net sales growth of only 3.82% annually over the last five years. The recent decrease in promoter stake by -5.11% also raises concerns about confidence in the company's future prospects.<BR><BR>In summary, the combination of poor stock performance relative to benchmarks, declining investor interest, weak fundamentals, and reduced promoter confidence are contributing to the falling stock price of Sandu Pharmaceuticals Ltd.

Why is Sandu Pharmaceuticals Ltd falling/rising?

As of 29-Mar, Sandu Pharmaceuticals Ltd's stock price is at 33.36, down 1.88%, with a one-year return of -27.84% compared to the BSE500's -5.18%. The company shows weak fundamentals, declining investor sentiment, and is trading below moving averages, indicating a negative outlook.

As of 29-Mar, Sandu Pharmaceuticals Ltd's stock price is falling, currently at 33.36, reflecting a change of -0.64 or -1.88%. The stock has underperformed significantly over various time frames, with a one-year return of -27.84%, which is starkly contrasted by the BSE500 benchmark's return of -5.18% during the same period. <BR><BR>The company's recent performance indicates a weak long-term fundamental strength, highlighted by an average Return on Equity (ROE) of only 3.73%. Additionally, the company's net sales have shown minimal growth, increasing at an annual rate of just 3.82% over the last five years. This lack of robust financial performance is further exacerbated by a poor EBIT to Interest ratio of 1.92, indicating challenges in servicing its debt.<BR><BR>Investor sentiment appears to be declining as well, with a notable drop in promoter confidence, as promoters have reduced their stake in the company by 5.11% in the previous quarter. This reduction may signal a lack of confidence in the company's future prospects. Furthermore, the stock is trading below its moving averages across various periods, suggesting a bearish trend.<BR><BR>Despite outperforming its sector by 0.52% today, the overall trading environment for the stock remains negative, with a significant drop in delivery volume, which has fallen by 61.73% against the five-day average. This decline in investor participation, combined with the company's consistent underperformance against benchmarks, contributes to the stock's current downward trajectory.

Which are the latest news on Sandu Pharma.?

Which are the latest news on Sandu Pharma.?

Which are the latest news on Sandu Pharma.?